PriceTracker GLP-1

FDA record · warning letter

FDA warning letter: Kare Solutions, LLC dba Zappy (Feb 20, 2026)

On Feb 20, 2026, FDA issued a warning letter to Kare Solutions, LLC dba Zappy of La Jolla, CA under the subject "False & Misleading Claims/Misbranded (Telehealth)". It names semaglutide, tirzepatide, liraglutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3
Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to Kare Solutions, LLC dba Zappy
FieldWhat FDA’s record statesSource
RecipientKare Solutions, LLC dba ZappyFDA letter
LocationLa Jolla, CAFDA letter
Letter dateFeb 20, 2026FDA letter
Posted by FDAMar 3, 2026FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectFalse & Misleading Claims/Misbranded (Telehealth)FDA letter
MARCS-CMS number717991FDA letter
GLP-1 drugs namedSemaglutide, Tirzepatide, LiraglutideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“The compounded semaglutide, tirzepatide, and liraglutide products displayed on your website identify “Zappy” on the pictured label, suggesting Zappy is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that Zappy is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”FDA warning letter to Kare Solutions, LLC dba Zappy, Feb 20, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

24HrDoc, Inc. dba 24HrDocFeb 20, 2026Alan Health Technologies Inc. dba AlanFeb 20, 2026Aspen Aesthetics dba Fifty 410Feb 20, 2026Belle Health LLC dba BelleFeb 20, 2026Better Health Labs, Inc. dba MeasuredFeb 20, 2026Bliv Wellness LLC dba BlivFeb 20, 2026BluefitMDFeb 20, 2026Deluxe IV Aesthetics PLLC dba Deluxe IV and AestheticsFeb 20, 2026Dripgym Mobile Parent, LLC dba Amp HealthFeb 20, 2026FitRX, LLC dba FitRxFeb 20, 2026Genesis Health International Inc. dba GenesisFeb 20, 2026Good Girl LLC dba GoodGirlRXFeb 20, 2026

And 17 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters